European Medicines Agency - Withdrawals of Application - Medicinal Products for Human Use - Zunrisa

GlaxoSmithKline withdraws its marketing authorisation application for Zunrisa (casopitant mesilate)
The European Medicines Agency has been formally notified by GlaxoSmithKline Research and Development Limited of its decision to withdraw its application for a centralised marketing authorisation for the medicine Zunrisa (casopitant mesilate), 50 mg and 150 mg film coated tablets.

abrir aquí para acceder al documento EMEA completo:
European Medicines Agency - Withdrawals of Application - Medicinal Products for Human Use - Zunrisa